Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 2221 AL 2235

Impaired dopamine release in Parkinson's disease

Cramb KML, Beccano-Kelly D, Cragg SJ, Wade-Martins R.

Brain. 2023 Aug 1;146(8):3117-3132. doi: 10.1093/brain/awad064.

Effects of white matter hyperintensity on cognitive function in PD patients: a meta-analysis

Zhao W, Cheng B, Zhu T, Cui Y, Shen Y, Fu X, Li M, Feng Y, Zhang S.

Front Neurol. 2023 Aug 9;14:1203311. doi: 10.3389/fneur.2023.1203311. eCollection 2023.

Is Gauchian genotyping of GBA1 variants reliable?

Tayebi N, Lichtenberg J, Hertz E, Sidransky E.

medRxiv [Preprint]. 2023 Oct 26:2023.10.26.23297627. doi: 10.1101/2023.10.26.23297627.

Editorial: Early detection of neurodegenerative disorders using behavioral markers and new technologies: New methods and perspectives

Manera V, Rovini E, Wais P.

Front Aging Neurosci. 2023 Feb 28;15:1149886. doi: 10.3389/fnagi.2023.1149886. eCollection 2023.

Drug-Resistant Parkinson's Disease in a Patient With Hereditary Hemochromatosis: A Case Report

Banta CW, Zonna X, Lott R, Jaisawal P, Elsisi A.

Cureus. 2023 Sep 1;15(9):e44530. doi: 10.7759/cureus.44530. eCollection 2023 Sep.

The relationship between depletion of brain GM1 ganglioside and Parkinson's disease

Sonnino S.

FEBS Open Bio. 2023 Sep;13(9):1548-1557. doi: 10.1002/2211-5463.13554. Epub 2023 Feb 5.

Monitoring Eye Movement in Patients with Parkinson's Disease: What Can It Tell Us?

Sun YR, Beylergil SB, Gupta P, Ghasia FF, Shaikh AG.

Eye Brain. 2023 Jul 24;15:101-112. doi: 10.2147/EB.S384763. eCollection 2023.

Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease

Texier B, Prime M, Atamena D, Belenguer P, Szelechowski M.

Neural Regen Res. 2023 Feb;18(2):293-298. doi: 10.4103/1673-5374.346487.

Translational molecular imaging and drug development in Parkinson's disease

Haider A, Elghazawy NH, Dawoud A, Gebhard C, Wichmann T, Sippl W, Hoener M, Arenas E, Liang SH.

Mol Neurodegener. 2023 Feb 10;18(1):11. doi: 10.1186/s13024-023-00600-z.

High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression

Tsukita K, Sakamaki-Tsukita H, Kaiser S, Zhang L, Messa M, Serrano-Fernandez P, Takahashi R.

Neurology. 2023 Oct 3;101(14):e1434-e1447. doi: 10.1212/WNL.0000000000207725. Epub 2023 Aug 16.

Hypothesizing mechanistic links between microbes and disease using knowledge graphs

Santangelo B, Bada M, Hunter L, Lozupone C.

bioRxiv [Preprint]. 2023 Dec 4:2023.12.01.569645. doi: 10.1101/2023.12.01.569645.

Neuronal DAMPs exacerbate neurodegeneration via astrocytic RIPK3 signaling

Chang NP, DaPrano EM, Evans WR, Nissenbaum M, McCourt M, Alzate D, Lindman M, Chou TW, Atkins C, Kusnecov AW, Huda R, Daniels BP.

bioRxiv [Preprint]. 2023 Jul 24:2023.07.21.550097. doi: 10.1101/2023.07.21.550097.

Evaluation of Nocturnal Symptoms in Chinese Parkinson's Disease Patients Based on the PDSS-2 Scale: A Multicenter Cross-Sectional Study

Su W, Huang P, Ma X, Shang H, Ye Q, Cheng O, Chan P, Liu C, Liu W, Tang B, Wang L, Zhang B, Wang T, Shao M, Xie A, Chen X, Zhu X, Wang J, Tao E, Chen S, Chen H.

J Parkinsons Dis. 2023;13(6):1061-1071. doi: 10.3233/JPD-230060.

Editorial: The UN international day of families: neurodegeneration as a result of genetic inheritance

Pacheva IH, Attili D, Ravanidis S.

Front Aging Neurosci. 2023 Oct 6;15:1291613. doi: 10.3389/fnagi.2023.1291613. eCollection 2023.

Differences in Survival across Monogenic Forms of Parkinson's Disease

Lanore A, Casse F, Tesson C, Courtin T, Menon PJ, Sambin S, Mangone G, Mariani LL, Lesage S, Brice A, Elbaz A, Corvol JC; French Clinicians Network for Parkinson's Disease Genetics (the PDG Group).

Ann Neurol. 2023 Jul;94(1):123-132. doi: 10.1002/ana.26636. Epub 2023 Mar 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias